Transcription of STABILITY TESTING OF ACTIVE PHARMACEUTICAL …
{{id}} {{{paragraph}}}
Example: barber
STABILITY TESTING OF ACTIVE PHARMACEUTICAL …
Working document January 2017. Draft document for comment 1 STABILITY TESTING OF ACTIVE . 2 PHARMACEUTICAL ingredients AND. 3 finished PHARMACEUTICAL PRODUCTS. 4 (January 2017). 5 DRAFT FOR COMMENT. Should you have any comments on the attached text and the STABILITY conditions for WHO Member States (MS) by Region, appendixed to the previous version of this guidance ( ), please send these to: Dr Sabine Kopp, Group Lead, Medicines Quality Assurance, Technologies Standards and Norms, World Health Organization, 1211 Geneva 27, Switzerland; email: fax: (+41 22) 791 4730;. and to Mrs Ksenia Finnerty by 15 March 2017. In line with the recommendations of the WHO Expert Committee on Specifications for PHARMACEUTICAL Preparations the list of MS STABILITY conditions is maintained as a living document. Comments received after the indicated date will also be considered.
Working document QAS/17.694 January 2017 Draft document for comment 1 STABILITY TESTING OF ACTIVE 2 PHARMACEUTICAL INGREDIENTS AND 3 FINISHED PHARMACEUTICAL PRODUCTS ...
Loading..
Tags:
Information
Domain:
Source:
Link to this page:
Please notify us if you found a problem with this document:
Related search queries
Stability testing of active pharmaceutical, Active pharmaceutical, Stability, Stability Testing of Pharmaceutical, Pharmaceutical, Stability testing of pharmaceutical products, STABILITY TESTING, STABILITY TESTING OF ACTIVE SUBSTANCES, Stability testing of active substances and pharmaceutical products, On stability testing for applications for, ICH HARMONISED TRIPARTITE GUIDELINE, Ich harmonised tripartite guideline stability testing, Registration of Medicines Stability, Registration of Medicines Stability Stability